|Title||Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Brewster, L, Robinson, S, Wang, R, Griffiths, S, Li, H, Peister, A, Copland, I, McDevitt, T|
|Journal||Journal of Vascular Surgery|
|Date Published||February 2016|
Critical limb ischemia (CLI) is a life- and limb-threatening condition affecting 1% to 10% of the population with peripheral arterial disease. Traditional revascularization options are not possible for up to 50% of CLI patients, in which case, the use of cellular therapies, such as bone marrow-derived mesenchymal stem cells (MSCs), hold great promise as an alternative revascularization therapy. However, no randomized, controlled phase 3 trials to date have demonstrated an improvement in limb salvage with cellular therapies. This may be due to poor cell quality (ie, inability to generate a sufficient number of angiogenic MSCs) or to the inadequate retention and viability of MSCs after delivery, or both. Because concerns remain about the expansion and angiogenic potential of autologous MSCs in the CLI population, the objective of this study was to examine the effect of our novel culture media supplement, pooled human platelet lysate (PL), in lieu of the standard fetal bovine serum (FBS), to improve the expansion potential of MSCs from CLI patients. We also characterized the in vitro angiogenic activity of MSCs from the tibia of amputated CLI limbs compared with MSCs from healthy donors.
|Alternate Journal||J. Vasc. Surg.|